Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: A retrospective analysis

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3078-3083

  Hutten, Barbara A ^a   Prins, Martin H ^a   Gent, Michae ^a   Ginsberg, Jeff ^a   Tijssen, Jan G P ^a   Büller, Harry R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0033850037     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3078     Document Type: Article

References (21)

1. Hemorrhagic and thrombotic abnormalities of cancer
2. Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment
3. Antithrombotic strategies in patients with cancer
4. Safety and efficacy of long-term oral anticoagulation in cancer patients
5. Anticoagulants, venous thromboembolism, and the cancer patient
6. Efficacy and safety of oral anticoagulation in patients with cancer
7. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants
8. Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants
9. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
10. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
11. A method to determine the optimal intensity of oral anticoagulant therapy
12. Hemorrhagic complications of anticoagulant therapy
13. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin
14. Bleeding complications in oral anticoagulant therapy
15. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota
16. Risk factors for bleeding during treatment of acute venous thromboembolism
17. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
18. Complications of oral anticoagulation in venous thromboembolic patients with or without malignancy: An analysis of the ISCOAT data
19. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
20. Treatment of thrombotic disorders in cancer patients
21. The long-term clinical course of acute deep venous thrombosis